Review Article

OPEN: Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II

The development of immune checkpoint inhibitors (ICIs) has changed the treatment paradigm for cancer. The ICIs nivolumab, pembrolizumab, and cemiplimab target programmed cell death protein 1, and durvalumab, avelumab, and atezolizumab target programmed death ligand 1. Ipilimumab targets cytotoxic T lymphocyte–associated antigen-4. Used as monotherapy or in combination, they have…